Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

Area of Science:

• Oncology
• Dermatology
• Cancer Research

Background:

• Melanoma incidence has increased, with metastatic melanoma historically having a poor prognosis.
• Recent advances in immunotherapy and targeted therapy have significantly improved survival rates for metastatic melanoma patients.
• Despite treatment advances, approximately 50% of patients exhibit primary or acquired resistance, leading to relapse.

Purpose of the Study:

• To review the molecular mechanisms underlying resistance to immunotherapy and targeted therapy in melanoma.
• To explore novel treatment strategies aimed at overcoming melanoma resistance.
• To enhance understanding of relapse patterns and resistance factors in melanoma treatment.

Main Methods:

• Literature review of recent clinical trials and research studies on melanoma treatment resistance.
• Analysis of molecular pathways and genetic factors implicated in melanoma therapeutic resistance.
• Synthesis of current and emerging treatment strategies to combat melanoma resistance.

Main Results:

• Immunotherapy and targeted therapy have transformed melanoma survival rates, exceeding 50% five-year survival.
• Mechanisms of primary and secondary resistance to these therapies are not fully elucidated but involve specific molecular pathways.
• Several genetic factors and molecular pathways are associated with treatment resistance in melanoma.
• Emerging strategies show promise in clinical trials for overcoming resistance and improving patient outcomes.

Conclusions:

• While current therapies have improved melanoma survival, resistance remains a significant clinical challenge.
• Further research into the molecular underpinnings of melanoma resistance is crucial for developing more effective treatments.
• Novel therapeutic strategies targeting resistance mechanisms are essential to further improve outcomes for melanoma patients.